Bicara Therapeutics Inc. ...

11.83
-1.43 (-10.78%)
At close: Apr 03, 2025, 3:59 PM
11.69
-1.18%
Pre-market: Apr 04, 2025, 04:26 AM EDT

Bicara Therapeutics Common Stock Statistics

Share Statistics

Bicara Therapeutics Common Stock has 54.52M shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding 54.52M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Institutions (%) n/a
Shares Floating -
Failed to Deliver (FTD) Shares 969.08K
FTD / Avg. Volume 213.56%

Short Selling Information

The latest short interest is 4.52M, so 8.31% of the outstanding shares have been sold short.

Short Interest 4.52M
Short % of Shares Out 8.31%
Short % of Float 13.89%
Short Ratio (days to cover) 6.93

Valuation Ratios

The PE ratio is -43.05 and the forward PE ratio is -8.13. Bicara Therapeutics Common Stock's PEG ratio is 0.72.

PE Ratio -43.05
Forward PE -8.13
PS Ratio 0
Forward PS 3.2
PB Ratio 5.95
P/FCF Ratio -39.13
PEG Ratio 0.72
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Bicara Therapeutics Common Stock.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 27.93, with a Debt / Equity ratio of 0.

Current Ratio 27.93
Quick Ratio 27.93
Debt / Equity 0
Debt / EBITDA -0.01
Debt / FCF -0.01
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-1.24M
Employee Count 55
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax -187K
Effective Tax Rate 0.28%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is -1.41, so Bicara Therapeutics Common Stock's price volatility has been lower than the market average.

Beta -1.41
52-Week Price Change null%
50-Day Moving Average 13.06
200-Day Moving Average null
Relative Strength Index (RSI) 40.87
Average Volume (20 Days) 453.77K

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -82.39M
Net Income -68M
EBITDA -82.39M
EBIT n/a
Earnings Per Share (EPS) -0.4
Full Income Statement

Balance Sheet

The company has 489.71M in cash and 738K in debt, giving a net cash position of 488.97M.

Cash & Cash Equivalents 489.71M
Total Debt 738K
Net Cash 488.97M
Retained Earnings -221.02M
Total Assets 524.17M
Working Capital 507.03M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -74.75M and capital expenditures -71K, giving a free cash flow of -74.82M.

Operating Cash Flow -74.75M
Capital Expenditures -71K
Free Cash Flow -74.82M
FCF Per Share -0.45
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

BCAX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for BCAX is $35, which is 195.9% higher than the current price. The consensus rating is "Buy".

Price Target $35
Price Target Difference 195.9%
Analyst Consensus Buy
Analyst Count 6
Stock Forecasts

Scores

Altman Z-Score 28.39
Piotroski F-Score 2